In addition, SETD2 inactivating mutations are more frequently found in advanced stage ccRCC tumors and correlate with increased tumor recurrence and worse cancer-specific survival [71, 124, 195]. This evidence concerns the gene SETD2 and nonpapillary renal cell carcinoma.